Comparison of outcomes following transhiatal or Ivor Lewis esophagectomy for esophageal carcinoma

Citation
L. Gluch et al., Comparison of outcomes following transhiatal or Ivor Lewis esophagectomy for esophageal carcinoma, WORLD J SUR, 23(3), 1999, pp. 271-276
Citations number
19
Categorie Soggetti
Surgery
Journal title
WORLD JOURNAL OF SURGERY
ISSN journal
03642313 → ACNP
Volume
23
Issue
3
Year of publication
1999
Pages
271 - 276
Database
ISI
SICI code
0364-2313(199903)23:3<271:COOFTO>2.0.ZU;2-U
Abstract
Transhiatal esophagectomy (THO) may be a valid alternative to the tradition al Ivor Lewis (ILO) procedure, but there have been reservations about proce dure mortality, nodal clearance, and survival. ILO is preferred for bulky m idesophageal lesions and THO in frail patients, making randomization diffic ult. This retrospective study compares results of a 10-year period from Jan uary 1985 with a minimum follow-up period of It months. Four patients were lost to follow-up. Preoperative nutritional markers were similar in the two groups, as were the age and sex distribution. Altogether 33 ILOs and 65 TH Os were performed. TNM staging was similar between groups, there being 43% stage II and 45% stage III lesions among the ILO patients and 53% stage II and 32% stage III disease in the THO group. Operating time was shorter for THO (256 +/- 58 minutes vs. 279 +/- 50 minutes) (p = 0.05); if two surgeons operated concurrently, THO could be performed 40 minutes quicker than THO or ILO performed by a single surgeon (p = 0.018), The mean initial intensiv e care unit stay was 2.9 days for ILO versus 1.7 days for THO (p = 0.014), The 30-day mortality was 5.1%; total in-hospital mortality was 7.1% with no difference for operation type. There were similar morbidity rates for the procedures. Kaplan-Meier survival analysis indicated no significant effect of surgical technique; there were no apparent advantages for either operati on when patients were compared by tumor type or matched for stage. Hence TH O is a valid alternative to ILO, particularly for stage II and III cancer.